



Published in final edited form as:

Nat Med. ; 18(2): 298–301. doi:10.1038/nm.2651.

## Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia

Panagiotis Ntziachristos<sup>1,2,\*</sup>, Aristotelis Tsirigos<sup>3,\*#</sup>, Pieter Van Vlierberghe<sup>4,5,6,\*</sup>, Jelena Nedjic<sup>1,2</sup>, Thomas Trimarchi<sup>1,2</sup>, Maria Sol Flaherty<sup>4</sup>, Dolores Ferres-Marco<sup>7</sup>, Vanina da Ros<sup>7</sup>, Zuojian Tang<sup>8,9</sup>, Jasmin Siegle<sup>1,2</sup>, Patrik Asp<sup>2</sup>, Michael Hadler<sup>4</sup>, Isaura Rigo<sup>4</sup>, Kim De Keersmaecker<sup>10,11</sup>, Jay Patel<sup>12</sup>, Tien Huynh<sup>3</sup>, Filippo Utro<sup>3</sup>, Sandrine Poglio<sup>13,14,15,16</sup>, Jeremy B. Samon<sup>4,5,6</sup>, Elisabeth Paietta<sup>17</sup>, Janis Racevskis<sup>17</sup>, Jacob M. Rowe<sup>18</sup>, Raul Rabadan<sup>19</sup>, Ross L. Levine<sup>12</sup>, Stuart Brown<sup>8,9</sup>, Francoise Pflumio<sup>13,14,15,16</sup>, Maria Dominguez<sup>7</sup>, Adolfo Ferrando<sup>4,5,6,\*#</sup>, and Iannis Aifantis<sup>1,2,\*#</sup>

<sup>1</sup>Howard Hughes Medical Institute and Department of Pathology, New York University School of Medicine, New York, NY 10016, USA

<sup>2</sup>NYU Cancer Institute and Helen and Martin S. Kimmel Stem Cell Center, New York University School of Medicine, New York, NY 10016, USA

<sup>3</sup>Computational Biology Center, IBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598, USA

<sup>4</sup>Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032 USA

<sup>5</sup>Department of Pathology, Columbia University Medical Center, New York, NY 10032 USA

<sup>6</sup>Department of Pediatrics, Columbia University Medical Center, New York, NY 10032 USA

<sup>7</sup>Instituto de Neurociencias de Alicante, Alicante 03550, Spain

<sup>8</sup>Department of Cell Biology, NYU School of Medicine, New York, NY 10016 USA

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

#Address Correspondence To: Iannis Aifantis, Ph.D., [iannis.aifantis@nyumc.org](mailto:iannis.aifantis@nyumc.org). Adolfo Ferrando, M.D., [af2196@columbia.edu](mailto:af2196@columbia.edu).

Aristotelis Tsirigos, Ph.D., [atsirigo@us.ibm.com](mailto:atsirigo@us.ibm.com).

\*These authors contributed equally to this work

Note: Supplementary information is available on the Nature Medicine website.

**Accession codes.** Microarray data are available in the Gene Expression Omnibus under accession code GSE34554.

### Author Contributions

I.A. and P.N. conceived the studies, directed research, analyzed the results and wrote the manuscript. P.N. performed xenograft experiments, isolated and characterized mouse samples and performed and analyzed the biochemical experiments helped by T.T. and J.S. A.T. directed research, analyzed data, developed computational methods and wrote the manuscript. J.N. isolated and characterized mouse samples, helped to project design and wrote manuscript. S.B. Z.T. and T.H. helped with the analysis of the genome-wide data. P.A. helped with the design and execution of the biochemical experiments. F.U. created the resource website. P.V.V., M.H., I.R., J.B.S. and J.P. performed mutation analysis of *SUZ12*, *EZH2* and *EED*. R.L. designed and supervised sequence analysis. P.V.V. performed xenograft experiments. P.V.V. and K.D.K. performed array-CGH analysis. R.R. analyzed array-CGH data. M.S.F. performed the genetic silencing studies of the PRC2 complex. E.P., J.R. and J.M.R. provided samples and correlative clinical data from ECOG. S.P. and F.P. performed and supervised experiments related to NOTCH activation into primary T-ALL samples and provided crucial materials. A.F. designed the studies, directed research and wrote the manuscript. D.F-M, V.dR., and M.D. designed and performed the Drosophila tumor experiments.

<sup>9</sup>Center for Health Informatics and Bioinformatics, NYU School of Medicine, New York, NY 10016 USA

<sup>10</sup>Department of Molecular and Developmental Genetics, VIB, Leuven 3000, Belgium

<sup>11</sup>Center for Human Genetics, K.U. Leuven, Leuven, 3000, Belgium

<sup>12</sup>Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA

<sup>13</sup>CEA, DSV-IRCM-SCSR-LSHL, UMR 967, F-92265 Fontenay-aux-Roses, France

<sup>14</sup>INSERM, U967, F-92265 Fontenay-aux-Roses, France

<sup>15</sup>Universite Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses, France

<sup>16</sup>Universite Paris-Sud, UMR 967, F-92265 Fontenay-aux-Roses, France Laboratoire des Cellules Souches Hématopoïétiques et Leucémiques, Institut de Radiobiologie Cellulaire et Moléculaire, INSERM U967; Université Paris 7 Denis Diderot; Commissariat à l'Energie Atomique (CEA), Fontenay-aux-Roses 92265, France

<sup>17</sup>Montefiore Medical Center North, Bronx, New York, NY 10467, USA

<sup>18</sup>Rambam Medical Center, Haifa, Israel

<sup>19</sup>Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, 10032, USA

## Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an immature hematopoietic malignancy driven mainly by oncogenic activation of NOTCH1 signaling<sup>1</sup>. In this study we report the presence of *loss-of-function* mutations and deletions of *EZH2* and *SUZ12* genes, encoding critical components of the Polycomb Repressive Complex 2 (PRC2) complex<sup>2,3</sup>, in 25% of T-ALLs. To further study the role of the PRC2 complex in T-ALL, we used NOTCH1-induced animal models of the disease, as well as human T-ALL samples, and combined locus-specific and global analysis of NOTCH1-driven epigenetic changes. These studies demonstrated that activation of NOTCH1 specifically induces loss of the repressive mark lysine-27 tri-methylation of histone 3 (H3K27me3)<sup>4</sup> by antagonizing the activity of the Polycomb Repressive Complex 2 (PRC2) complex. These studies demonstrate a tumor suppressor role for the PRC2 complex in human leukemia and suggest a hitherto unrecognized dynamic interplay between oncogenic NOTCH1 and PRC2 function for the regulation of gene expression and cell transformation.

---

T-ALL is a hematologic malignancy<sup>5,6,7</sup> characterized by activating mutations in the *NOTCH1*<sup>8</sup> gene and alterations in the *FBXW7*<sup>9</sup> ligase resulting in activation of Notch signaling. Although the importance of NOTCH activation in T-ALL is well established, the detailed molecular mechanisms mediating NOTCH1-induced transformation remain unknown. We hypothesized that NOTCH1 interacts with epigenetic modulators to control gene expression. In addition, we proposed that genetic alterations in key components of the epigenetic machinery could amplify oncogenic signals. To test this notion, we analyzed an extensive series of array comparative genomic hybridization (aCGH) data on adult T-ALL

primary samples for the presence of recurrent deletions encompassing genes involved in epigenetic regulation. This analysis revealed the presence of recurrent deletions involving genes encoding core components of the Polycomb Repressive Complex 2 (PRC2). This complex is the “writer” of a major repressive chromatin modification, Lysine 27 trimethylation on Histone 3 (H3K27me3). We found recurrent deletions encompassing the *EZH2*<sup>10–12</sup> and *SUZ12*<sup>13,14</sup> loci (Supplementary Fig. 1 and Supplementary Table 1). Following these results we screened primary tumor DNA samples for the presence of somatic mutations affecting the core components of the PRC2 complex<sup>15</sup>. This analysis revealed the presence of truncating or missense mutations in both *EZH2* (11/68) and *SUZ12* (3/68). *EZH2* mutations included four non-synonymous single-nucleotide substitutions, one nonsense mutation and six frameshift-creating insertions and deletions (Fig. 1a,b, Supplementary Fig. 1 and Supplementary Table 1). *SUZ12* mutations identified in T-ALL included 2 missense and 1 frameshift mutation (Fig. 1c,d). *Loss of function* mutations and deletions in *EZH2* have been previously associated with myeloid leukemias<sup>10–12</sup>. In contrast, *gain of function* *EZH2* mutations involved in B-cell lymphomas are typically single amino acid substitutions involving Y641<sup>16,17</sup>. Nonsense and frameshift mutations in *EZH2* and *SUZ12* in T-ALL are prototypical *loss of function* truncating alleles consistent with a PRC2 tumor suppressor role for these genes in T-cell transformation. Notably, 7 *EZH2* and 3 *SUZ12* mutations were heterozygous but also 4 out of 11 *EZH2* and 1 out of 3 *SUZ12* mutations were homozygous<sup>18</sup>. In all 8/14 cases (6 *EZH2* and 2 *SUZ12* variants) with available matched bone marrow remission genomic DNA we confirmed the somatic origin of the *EZH2* and *SUZ12* mutations (Fig. 1a,c and Supplementary Table 1). The convergent findings of our re-sequencing effort and copy number analysis thus identified *EZH2* and *SUZ12* as novel tumor suppressor genes mutated and deleted in T-ALL. Overall, genetic lesions targeting *EZH2* or *SUZ12* were identified in 17/68 (25%) of primary T-ALL samples (Fig. 1e). The complete absence of *EZH2* protein in both cases with combined deletion and mutation of the *EZH2* gene examined (Fig. 1f) revealed that these *loss of function* mutations and suggested that inactivation of the PRC2 complex may constitute an important pathogenetic event in human T-ALL. Further targeted re-sequencing revealed that PRC2 genetic alterations were frequently (in 65% of the cases) associated with oncogenic *NOTCH1* mutations (Supplementary Table 1). This frequency suggested that the two events could directly or indirectly co-operate. We analyzed the effects of PRC2 inactivation in the expression of prototypical *NOTCH1* target genes such as *HES1* and *DTX1* in T-ALL cell lines harboring *NOTCH1* mutations<sup>9,19</sup>. These experiments showed that silencing of both *EZH2* and *SUZ12* resulted in transcriptional upregulation of both target genes (Fig. 1g, Supplementary Fig. 2 and not shown), suggesting that loss of PRC2 could potentiate the *NOTCH1* transcriptional program.

To further explore the role of the PRC2 complex in Notch target expression and T-ALL induction/progression we aimed to dissect the epigenetic changes associated with transformation in T-ALL. Chromatin Immunoprecipitation (ChIP) studies using CUTLL1 cells<sup>15</sup>, a human T-ALL line<sup>20</sup> characterized by a Notch1 translocation showed that *NOTCH1* binding on the promoter of *HES1*, a canonical *NOTCH1* target required for *NOTCH1*-induced transformation<sup>5,21</sup> (Supplementary Fig. 3 and Supplementary Table 2), peaks at –50 to –100 bp relative to the Transcriptional Start Site (TSS) followed by

enrichment of RNA Polymerase II (POL II) (Supplementary Fig. 3). No binding for NOTCH1 or POL II was observed in a NOTCH1-negative T-ALL cell line (Supplementary Fig. 3b,c). Inhibition of the Notch1 signaling using a  $\gamma$ -secretase inhibitor ( $\gamma$ SI)<sup>20</sup> (Supplementary Fig. 4a) abrogated NOTCH1 binding on the *HES1* promoter and led to decreased levels of *HES1* mRNA expression (Supplementary Fig. 4b,c). Subsequent  $\gamma$ SI removal restored high levels of NOTCH1, POL II and the activating mark acetylation of Lysine 9 of Histone 3 (H3K9ac) on the *HES1* promoter as well as *HES1* expression (Supplementary Fig. 4b–e).

To further test the interplay between activation of NOTCH1 and epigenetic regulation we used a Notch1-IC-induced T-ALL animal model<sup>22</sup>, which recapitulates most of the features of human T-ALL (Fig. 2a and Supplementary Fig. 5a-c). Most *Notch1*-induced leukemias show a double positive (DP) phenotype characterized by the expression of both CD4 and CD8 co-receptors (Fig. 2b). To study the transcriptional and epigenetic changes in *Hes1* during Notch1 driven leukemogenesis we compared FACS-sorted DP Notch1-transformed cells (T-ALL) to normal DP thymocytes, which show low levels of Notch1 and *Hes1* activation (Fig. 2b,c). Scanning of the murine *Hes1* promoter revealed significant enrichment for Notch1 binding in T-ALL compared to DP (Fig. 2e) accompanied by enrichment of PolIII on the TSS (Fig. 2f). Moreover, ChIP experiments showed enrichment of the activating acetylation of lysine 9 on H3 (H3K9ac)<sup>23</sup> and trimethylation of lysine 4 on H3 (H3K4me3)<sup>24</sup> (Fig. 2g,h) around the *Hes1* TSS, followed by enrichment for the transcriptional elongation-associated form of Pol II (Serine 2-Phosphorylated Pol II, S2-P-Pol II) and trimethylation of lysine 36 on histone 3 (H3K36me3) on the gene body (Fig. 2i). One of the most prominent differences, however, was the loss of the repressive H3K27me3 from the *Hes1* promoter in the leukemic cells that was accompanied by gain of acetylation of the same residue (Fig. 2j), an activating epigenetic mark<sup>25</sup>. Similar results were obtained for *Deltex1* (*Dtx1*), which is also a direct Notch1 target gene (Supplementary Fig. 6), but not on the *Gapdh* locus, used as a control. These results demonstrated that Notch1-mediated oncogenic transformation was coupled to epigenetic changes, including the loss of the H3K27me3 histone mark from Notch target gene promoters.

To test whether the *Hes1* behavior is part of a wider Notch1 driven epigenetic reprogramming in leukemic cells, we performed whole transcriptome profiling (Supplementary Tables 3,4) and ChIP-Sequencing (ChIP-Seq, Supplementary Table 5) for H3K4me3, H3K9ac and H3K27me3 (Fig. 3a,b and Supplementary Fig. 7). Computational validation of ChIP-Seq results showed high correlation of the biological replicates (Supplementary Fig. 7a) and consistency with gene expression (Supplementary Fig. 8,9). Enrichment analyses (Supplementary Tables 6–9) revealed that the regulated (and marked by modifications) genes belong in functional categories related to normal T cell differentiation and T cell transformation (Fig. 3c and Supplementary Fig. 10). Genes up-regulated in Notch1-driven leukemic cells compared to normal DP thymocytes were primarily characterized by loss of H3K27me3 ( $P=6.91 \times 10^{-22}$ ). Unexpectedly, gain of H3K9ac in these genes was much less significant ( $P=1.52 \times 10^{-4}$ ) (Fig. 3a,b and Supplementary Tables 10,11), suggesting that loss of H3K27me3 is the most prominent epigenetic change coupled to gene activation. This in turn, provided evidence for a central

role of PRC2 in T-ALL. On the contrary, down-regulated genes showed primarily loss of H3K9ac ( $P=2.79 \times 10^{-19}$ , Supplementary Tables 11,12). Most notably, the loss of H3K27me3 from the TSS region of T-ALL up-regulated transcripts was not due to lower total levels of the H3K27me3 in T-ALL (Supplementary Fig. 11 and Supplementary Table 5). Changes in H3K4me3 seemed to have a lesser role related to context-dependent and fine-tuning regulation of gene expression (Fig. 3a,b and Supplementary Table 11). Targets of Notch1, such as *Hes1*, *Dtx1*, *Pre-TCR alpha (Ptcra)* and *c-Myc*, exhibited loss of H3K27me3, whereas the changes of H3K4me3 and H3K9ac were more subtle (Fig. 3d and Supplementary Fig. 12), suggesting a functional interaction between Notch1 and loss of H3K27me3, generally associated with decreased activity of the PRC2 complex.

To further explore the role of Notch1 in driving the loss of H3K27me3 we performed ChIP-Seq for Notch1 (Fig. 4a and Supplementary Fig. 13). Whereas no significant peaks were detected in DP, analysis of Notch1-transformed T-ALL lymphoblasts revealed a large number of direct Notch1 binding events. Importantly, H3K27me3 loss in T-ALL was broadly overlapping with direct Notch1 binding in TSS regions (Fig. 4a,b). The lack of enrichment of H3K9ac gain or loss suggested that Notch1 binding is highly specific to H3K27me3 loss (Fig. 4a). The observed loss of H3K27me3 in Notch1 targets is mainly localized in a narrow region around TSSs (Fig. 4b). Loss of H3K27me3 was observed specifically on Notch1 targets and not in the whole T-ALL genome (Fig. 4a and Supplementary Figs 14 and 15). These combined data suggested that significant loss of H3K27me3 is a hallmark of the oncogenic function of Notch1 in T-ALL.

The rapid increase of Notch1-IC levels in human T-ALL lines upon  $\gamma$ SI removal (Supplementary Fig. 4) resulted in a dynamic and rapid loss of the H3K27 (Fig. 4c and Supplementary Fig. 16), further proving the inverse correlation of the two events. This led us to further investigate this relationship in additional human T-ALL cell lines and primary T-ALL samples. Initially we screened additional T-ALL lines (DND41 and CEM), exhibiting high N1-IC and *HES1* expression, and normal (*HES1<sup>low</sup>*) human thymocytes (Fig. 4d). The levels of H3K27me3 were once more inversely correlated with *HES1* expression (Fig. 4d). To exclude the possibility that these results were due to cell line artifacts, we studied primary samples whose high leukemogenic potential was evaluated using transplantation (Fig. 4e and Supplementary Fig. 17). The primary T-ALL leukemic blasts exhibited higher levels of *HES1* compared to normal human thymocytes and the levels of H3K27me3 were inversely correlated with *HES1* expression (Fig. 4f). These studies demonstrated that the correlation between oncogenic NOTCH1 binding and loss of H3K27me3 is a universal characteristic of T-ALL.

We then focused on the relationship between oncogenic NOTCH1 with the PRC2 complex. Initially, the analysis revealed that Notch1 binding sites are enriched for PRC2 targets (4.3-fold enrichment and  $P=8.45 \times 10^{-110}$ , Supplementary Table 9). Moreover, we analyzed the effects of Notch1 activation on the occupancy of Notch1 target genes by the EZH2 catalytic subunit of PRC2. These studies demonstrated that Notch1 binding led to significant Ezh2 eviction from the *Hes1* promoter (Fig. 4g). This could not be attributed to lower EZH2 expression in the cancer cells (Supplementary Fig. 18a). ChIP analysis for SUZ12 binding yielded identical results (Fig. 4h). EZH2 eviction and H3K27 loss was not only a feature of

the Notch1-IC model utilized, as identical results were obtained using “weaker” human Notch1HD/PEST alleles in *in vivo* disease models (Supplementary Fig. 19). These epigenetic effects were observed even at the very early stages of the disease (Supplementary Fig. 20). Moreover, down-regulation of N1-IC levels by  $\gamma$ SI treatment, led to a marked decrease of EZH2 binding on the *HES1* or *DTX1* promoters (Supplementary Fig. 18). Also, the binding of JARID2<sup>26,27</sup>, one of the recruiters of the PRC2 complex to DNA, on the *HES1* promoter was also inversely correlated to Notch1 binding (Fig. 4i). These responses were rapid, as significant changes in Notch1 binding and PRC2 recruitment were detected as early as 30min upon  $\gamma$ SI removal (Supplementary Fig. 21). The reverse correlation between Notch1-PRC2 binding and H3K27me3 levels was found in all T-ALL lines studied (Supplementary Fig. 22). Identical epigenetic changes were also noted when the Notch pathway was inhibited using a dominant negative form of MAML1 (Supplementary Fig. 23).

The presented mechanistic interaction between NOTCH1 and the PRC2 complex suggested a potential role for PRC2 mutations in NOTCH-induced transformation, although Notch-independent effects are also possible. To start addressing pathway interaction, we used a *Drosophila* Notch-driven tumor model<sup>28</sup> to evaluate the impact of knockdown of *E(z)* in cells that express weak activating alleles of Notch (Supplementary Fig. 24). We were able to show that the combination of Notch activation and *E(z)* loss resulted in eye tumor overgrowth<sup>28,29</sup> in approximately 50% of the progeny ( $n = 64$ )<sup>30</sup>. In agreement with such a notion of cooperation between Notch and PRC2 loss we were able to show that: EZH2 silencing resulted in decreased apoptosis triggered by  $\gamma$ SI inhibition of Notch signaling in human T-ALL lines (Supplementary Fig. 25). Moreover, EZH2 silencing increased the *in vivo* tumorigenic potential of T-ALL cells and led to enhanced mortality in transplantation experiments (Supplementary Fig. 26). These studies suggested a striking conservation of the Notch:PRC2 pathway interaction in tumorigenesis and further established the role of the PRC2 complex as a tumor suppressor in T-ALL, although the exact mechanisms of function have to be detailed further. We believe that our studies offer new therapeutic avenues for the treatment of T cell leukemia<sup>31,32</sup> as inhibitors of H3K27 demethylases<sup>33</sup>, alone or in combination with targeted anti-Notch1 therapies, could antagonize oncogenic Notch1 function and be further exploited for the treatment of T-ALL.

## Methods

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturemedicine/>.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We would like to thank Drs. R. Bonasio and D. Reinberg (HHMI and NYU School of Medicine) for critical reading of the manuscript and sharing reagents; C. Siebel (Genentech) for critical reagents; P. Ballerini, C. Deswartes, T. Leblanc and A. Baruchel (Services d'Hématologie Pédiatrique, Hôpital Saint-Louis, Hôpital Robert Debré and Hôpital Trousseau, AP-HP, Paris, France) for providing primary T-ALL patient samples. M. Gialitakis, L. Parida


and G. Stolovitzky for comments on the manuscript; J. Zavadil, B. Berrin and the NYU Genome Technology Center (supported in part by NIH/NCI P30 CA016087-30 grant) for expert genomic assistance. The NYU Flow Cytometry facility (supported in part by NIH/NCI 5 P30CA16087-31) for expert cell sorting. Also, the NYU Histology Core (5P30CA16087-31), and the Transgenic Mouse Core (NYU Cancer Institute Center Grant (5P30CA16087-31)). J.N. was supported by the Damon Runyon Cancer Research Foundation. I.A. was supported by the National Institutes of Health (RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655, and RO1GM088847), The Leukemia & Lymphoma Society, The V Foundation, the American Cancer Society (RSG0806801) and the Dana Foundation. The Laboratory is also supported by a Feinberg Lymphoma Pilot grant. Also, his study was supported by the Fund for Scientific Research (FWO) Flanders (P.V.V. and K.D.K); the National Library of Medicine (1R01LM010140-01 to R.R.); the ECOG tumor bank; a Northeast Biodefence Center ARRA award (U54-AI057158 to R.R.); the National Institutes of Health (R01CA120196 and R01CA155743 to A.F.); the Stand Up To Cancer Innovative Research Award (A.F.), the Chemotherapy Foundation (I.A. and A.F.); the Rally Across America Foundation (A.F) and the Swim Across America Foundation (A.F.). P.V.V is an ASH Scholar and I.A. and A.F. are Leukemia & Lymphoma Society Scholars. MD is supported by grants from Spanish Ministerio de Ciencia e Innovación (BFU2009-09074 and MEC-CONSOLIDER CSD2007-00023), Generalitat Valenciana (PROMETEO2006/134) and a European Union Research Grant (UE-HEALTH-F2-2008-201666). P.F is supported by the Institut du Cancer (INCA), the Association Laurette Fugain, the Ligue National Contre le Cancer, and also by INSERM, CEA, and StemPole. S.P. is supported by a fellowship by INCA. I.A. is a Howard Hughes Medical Institute Early Career Scientist.

## References


1. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. *J Pathol.* 2011; 223:262–273. [PubMed: 20967796]
2. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. *Nature.* 2011; 469:343–349. [PubMed: 21248841]
3. Orlando V. Polycomb, epigenomes, and control of cell identity. *Cell.* 2003; 112:599–606. [PubMed: 12628181]
4. Barski A, et al. High-resolution profiling of histone methylations in the human genome. *Cell.* 2007; 129:823–837. [PubMed: 17512414]
5. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. *Nat Rev Immunol.* 2008; 8:380–390. [PubMed: 18421304]
6. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. *Blood Rev.* 2010
7. Carpenter AC, Bosselut R. Decision checkpoints in the thymus. *Nat Immunol.* 2010; 11:666–673. [PubMed: 20644572]
8. Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science.* 2004; 306:269–271. [PubMed: 15472075]
9. Thompson BJ, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. *J Exp Med.* 2007; 204:1825–1835. [PubMed: 17646408]
10. Chase A, Cross NC. Aberrations of EZH2 in cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research.* 2011; 17:2613–2618. [PubMed: 21367748]
11. Ernst T, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. *Nature genetics.* 2010; 42:722–726. [PubMed: 20601953]
12. Nikoloski G, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. *Nature genetics.* 2010; 42:665–667. [PubMed: 20601954]
13. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. *Genes Dev.* 2006; 20:1123–1136. [PubMed: 16618801]
14. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. *Mol Cell.* 2004; 15:57–67. [PubMed: 15225548]
15. Chase A, Cross NC. Aberrations of EZH2 in cancer. *Clin Cancer Res.* 2011; 17:2613–2618. [PubMed: 21367748]
16. Yap DB, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. *Blood.* 2011; 117:2451–2459. [PubMed: 21190999]

17. Morin RD, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nature genetics*. 2010; 42:181–185. [PubMed: 20081860]
18. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. *Nature*. 2011; 476:163–169. [PubMed: 21833082]
19. Sulis ML, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. *Blood*. 2008; 112:733–740. [PubMed: 18411416]
20. Palomero T, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. *Proc Natl Acad Sci U S A*. 2006; 103:18261–18266. [PubMed: 17114293]
21. Wendorff AA, et al. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. *Immunity*. 2010; 33:671–684. [PubMed: 21093323]
22. Buonamici S, et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. *Nature*. 2009; 459:1000–1004. [PubMed: 19536265]
23. Kuo MH, et al. Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines. *Nature*. 1996; 383:269–272. [PubMed: 8805705]
24. Santos-Rosa H, et al. Active genes are tri-methylated at K4 of histone H3. *Nature*. 2002; 419:407–411. [PubMed: 12353038]
25. Rada-Iglesias A, et al. A unique chromatin signature uncovers early developmental enhancers in humans. *Nature*. 2010
26. Peng JC, et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. *Cell*. 2009; 139:1290–1302. [PubMed: 20064375]
27. Landeira D, et al. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. *Nat Cell Biol*. 2010; 12:618–624. [PubMed: 20473294]
28. Ferrer-Marco D, et al. Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. *Nature*. 2006; 439:430–436. [PubMed: 16437107]
29. Palomero T, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. *Nat Med*. 2007; 13:1203–1210. [PubMed: 17873882]
30. Dietzl G, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in *Drosophila*. *Nature*. 2007; 448:151–156. [PubMed: 17625558]
31. Lopez J, Percharde M, Coley HM, Webb A, Crook T. The context and potential of epigenetics in oncology. *Br J Cancer*. 2009; 100:571–577. [PubMed: 19223907]
32. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. *Nat Med*. 2011; 17:330–339. [PubMed: 21386836]
33. Natoli G, Testa G, De Santa F. The future therapeutic potential of histone demethylases: A critical analysis. *Curr Opin Drug Discov Devel*. 2009; 12:607–615.
34. Rahl PB, et al. c-Myc regulates transcriptional pause release. *Cell*. 2010; 141:432–445. [PubMed: 20434984]
35. Creighton MP, et al. H2AZ is enriched at polycomb complex target genes in ES cells and is necessary for lineage commitment. *Cell*. 2008; 135:649–661. [PubMed: 18992931]
36. Klinakis A, et al. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. *Proc Natl Acad Sci U S A*. 2006; 103:9262–9267. [PubMed: 16751266]
37. Tu Y, Stolovitzky G, Klein U. Quantitative noise analysis for gene expression microarray experiments. *Proc Natl Acad Sci U S A*. 2002; 99:14031–14036. [PubMed: 12388780]
38. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2010; 26:589–595. [PubMed: 20080505]
39. Tsirigos A, Haiminen N, Bilal E, Utro F. GenomicTools: a computational platform for developing high-throughput analytics in genomics. *Bioinformatics*. 2011
40. Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol*. 2008; 9:R137. [PubMed: 18798982]




**Figure 1.**


The PRC2 complex as a tumor suppressor in T-ALL. **(a)** Structure of the *EZH2* protein including 2 SANT DNA binding domains, the cysteine-rich CXC domain and the catalytic SET domain. Overview of all *EZH2* mutations identified in primary T-ALL samples. Filled circles: nonsense and frameshift mutations, open circles: missense mutations. **(b)** Representative chromatograms of paired diagnosis and remission genomic DNA samples showing somatic mutations in exon 8 and exon 10 of *EZH2*. **(c)** Structure of the *SUZ12* protein including a zinc finger domain and the VEFS domain. **(d)** Representative DNA sequencing chromatograms showing a frame-shift mutation in exon 10 of *SUZ12* and of paired diagnosis and remission genomic DNA samples showing a somatic point mutation in exon 14 of this gene. **(e)** Pie-chart summarizing the frequencies of homozygous and heterozygous mutations of *EZH2* and *SUZ12* in adult TALL patients. **(f)** *EZH2* protein levels in samples from patients (#1 and #4) with mutations and deletions on the *EZH2* gene compared to WT controls. **(g)** Silencing of *EZH2* and *SUZ12* in the Jurkat human T-ALL line. HES1 and DTX1 mRNA expression levels followed silencing of either *SUZ12* or *EZH2*. Knockdown of the luciferase (*LUC*) gene was used as a control.



**Figure 2.** Notch1-induced epigenetic changes in an *in-vivo* model of T-ALL. (a) Comparison of the size of the thymus in leukemic animals and control littermates. (b) Cell populations used in this study. (c) Western blot showing the expression of N1-IC in DP and T-ALL cells. (d) *Hes1* cDNA levels between DP and T-ALL. (e, f) ChIP of Notch1 and Pol II on the *Hes1* promoter in the indicated cell populations. (g-j) ChIP of the indicated histone marks and S2-P-Pol II in DP and T-ALL cells.

**Figure 3.**

Characterization of T-ALL epigenetic landscape using ChIP-Seq for H3K9ac, H3K4me3 and H3K27me3. **(a)** Cluster of the major gene expression changes between T-ALL and DP and the accompanied epigenetic changes. Left part: Expression heatmap representing up (red)- and down (blue)-regulated genes with significant epigenetic changes. Right panel: Heatmap representation of the epigenetic marks in T-ALL and DP in TSSs of selected genes. “+”:gain and “-”:loss in the levels of epigenetic mark in T-ALL versus DP. Loss of H3K27me3 ( $P=6.91 \times 10^{-22}$ , blue bar) and gain of H3K9ac ( $P=1.52 \times 10^{-4}$ , green bar) are enriched in up-regulated genes, whereas loss of H3K9ac ( $P=2.79 \times 10^{-19}$ , red bar) is enriched in down-regulated genes. **(b)** Bar graphs indicate the percentage of genes characterized by each modification in T-ALL cells. The plus and minus signs are used as above. Pink and blue frames: prevalent epigenetic clusters in down-regulated and up-regulated genes, respectively. **(c)** Functional annotation of epigenetic changes (T-ALL vs DP) in H3K9ac (yellow bars) and H3K4me3 (gray bars) shows enrichment in specific biological processes. **(d)** ChIP-Seq results for two well-characterized Notch1 targets, *Hes1* and *Dtx1* (arrows denote the TSS).

**Figure 4.**

Notch1 binding mediates loss of H3K27me3 and eviction of PRC2 in T-ALL. (a) Enrichment of Notch1 binding sites around TSSs characterized by each indicated histone mark. (b) H3K27me3 average signal profiles around TSS areas (blue line: Notch1-bound genes, gray line: genes not-bound by Notch1). (c) ChIP for H3K27me3 in a T-ALL cell line (CUTLL1) treated with  $\gamma$ SI. The Loucy T-ALL line is used as a negative control. (d) *HES1* expression in the indicated cell lines and normal human thymocytes and ChIP for H3K27me3 in the indicated cell lines and primary cells. (e) High leukemogenic potential of the human T-ALL samples in xenograft models. Spleen sections of recipient mice stained with an hCD45 antibody or an IgG control. (f) qPCR for *HES1* expression and the levels of H3K27me3 in primary human T-ALL samples and human thymocytes ( $P < 0.0001$  between M69 and the human thymus). (g) ChIP experiments for Ezh2 on the *Hes1* promoter in DP (green) and T-ALL (red). (h) Suz12 binding on the *Hes1* promoter. (i)  $\gamma$ SI-mediated changes of the N1-IC levels modulate JARID2 recruitment to the *HES1* promoter ( $P = 0.059$ ).